The De-Rating

Zoetis, and a Halved Share Price

Zoetis is the world's largest animal health company: a patent-protected, high-return franchise that turned about 28 cents of every revenue dollar into profit in 2025 and earned a 78% return on equity. Yet its shares have fallen roughly 69% from their 2021 peak to about $76, most of that in the last year, after U.S. companion-animal demand softened and management cut its outlook twice. This report exists to weigh whether that de-rating has gone too far, or not far enough.

What Zoetis is

Zoetis discovers, develops, manufactures and sells medicines, vaccines, diagnostics and genetic tests for animals. It works across eight core species — dogs, cats and horses on the companion-animal side; cattle, swine, poultry, fish and sheep on the livestock side — and seven product categories including parasiticides, vaccines, dermatology and pain treatments [1]. The company was carved out of Pfizer, incorporated in Delaware in 2012 and taken public in a 2013 IPO [2]. It has no founder and no controlling shareholder; the register is institutional.

The revenue mix has tilted steadily toward pets. Companion-animal products made up about 70% of 2025 revenue, with livestock most of the balance and a small contract-manufacturing and human-health diagnostics line [3]. That tilt is the growth story and, lately, the problem: companion animal has been the engine, and it is where demand has cooled.

Source: derived from reported segment revenue, FY2022–FY2025 [4].

Revenue is concentrated in a handful of brands. In 2025 the parasiticide line Simparica and Simparica Trio contributed about 16% of revenue, and the dermatology drug Apoquel about 12%; the top five products and lines — adding the dermatology antibody Cytopoint, the osteoarthritis-pain antibody Librela and the ceftiofur anti-infective line — reached roughly 42%, and the top ten about 57% [5]. A concentrated, patented portfolio is the source of the margins — and the reason a competitive or safety problem in any one franchise carries weight.

The economics that earned a premium

The business is unusually profitable. On $9.47 billion of 2025 revenue Zoetis earned $2.67 billion of net income and $6.03 in basic EPS [6]. Net margin was about 28%, return on equity about 78%, and the company converted revenue to roughly $2.3 billion of free cash flow.

Source: FY2025 reported results [7]; free cash flow and returns derived from reported financials; P/E at a share price near $76.

Those returns rest on scale and patents. Zoetis is the largest company in animal health by revenue and competes with Boehringer Ingelheim, Merck Animal Health, Elanco and, in diagnostics, IDEXX [8]. It also carries the standing risk of any drug business: when patents lapse, generics take share. The company's own filing shows how sharply — U.S. sales of its older Rimadyl and Draxxin products fell 39% and 66% respectively after generic entry [9].

Revenue and earnings compounded steadily through 2024. The break came in 2025.

Source: reported results, FY2019–FY2025 [10].

Growth stalled first

Reported revenue growth slowed to about 2% in 2025 from 8% in 2024. The first quarter of 2026 confirmed the deceleration was demand-led, not currency: organic operational revenue was flat, U.S. revenue fell 8%, and companion-animal revenue declined 4% [11].

Source: derived from reported revenue, FY2020–FY2025 [12]. Growth here is reported and includes currency and acquisitions; the company guides on organic operational growth.

Management named four converging pressures in the first quarter: rising vet-clinic prices against lower clinic traffic; pet owners growing more price-sensitive toward premium preventative and chronic-care products, where Zoetis is over-indexed; intensified competition in dermatology, parasiticides and vaccines, with more entrants pricing aggressively; and, unusually, those entrants taking share without expanding the overall market [13]. A separate overhang sits on the osteoarthritis-pain antibody Librela, which the FDA flagged for adverse-event reports in dogs in late 2024; international Librela sales fell 7% in the first quarter of 2026 [14].

The company cut its full-year 2026 outlook to organic operational revenue growth of 2% to 5% and adjusted net income growth of 2% to 6%, and launched a cost-and-productivity program [15]. For a business the market had valued as a high-single-digit-to-low-teens grower, a 2%-to-5% year is a sharp step down from the growth that had been priced in.

The de-rating

The share price tells the story more starkly than the fundamentals. Zoetis peaked near $247 at the end of 2021 and traded around $76 in mid-July 2026 — a fall of roughly 69%, with the sharpest leg in the twelve months to mid-2026 as the guidance cuts landed.

Source: company share-price history, year-end closes 2013–2025 and mid-July 2026, as reported.

The de-rating is a multiple story, not an earnings collapse. Earnings are near record levels, yet the stock trades at about 12.6 times trailing EPS and roughly 11 times the consensus 2026 estimate of about $6.86 — well below the low-to-mid-30s multiples Zoetis carried for most of its public life. In multiple terms, that is a compression to roughly a third of its former level, on earnings that are near record highs.

Sell-side opinion has softened but not capitulated: the consensus price target sits near $115, with a low estimate of about $80 still above the current price, and the ratings split roughly 11 buy to 9 hold with no sells. The market is pricing a serious slowdown, not a broken business.

Source: consensus analyst estimates and price targets, as of mid-2026.

Capital allocation reflects management's own read that the shares are cheap. Under a $6 billion program authorized in 2024, Zoetis repurchased 23.9 million shares for $3.2 billion in 2025, leaving $2.4 billion of authorization [16]; it also pays a $0.50 quarterly dividend [17]. Much of that 2025 buyback was executed at prices well above today's, a tension a later chapter on capital allocation should weigh.

The question this report answers

Zoetis presents the classic fallen-quality setup: a durable, high-return, patent-protected leader in a structurally growing market — pet ownership and pet-care spending — whose shares have halved as growth decelerated and competition and demand pressures converged. The central question every chapter that follows connects to is this: is the de-rating in Zoetis pricing a temporary demand-and-competition air pocket in a business that resumes high-single-digit growth and high returns, or the early evidence that its growth algorithm — premium pricing, patent-protected franchises, expanding companion-animal demand — is structurally slowing? The answer turns on the durability of the moat, the depth and duration of the U.S. demand and competitive pressure, the credibility of the pipeline management points to for 2027–2028, and the margin of safety in a low-double-digit multiple on still-growing earnings.